Schultze Joachim L, Grabbe Stephan, von Bergwelt-Baildon Michael S
Molecular Tumor Biology and Tumor Immunology, Clinic I for Internal Medicine, University Hospital Cologne, University of Cologne, Joseph Stelzmann Strasse 9, 50931 Cologne, Germany.
Trends Immunol. 2004 Dec;25(12):659-64. doi: 10.1016/j.it.2004.09.016.
Despite the still poorly understood complexity of tumor-host immune interactions, the use of cellular vaccines (particularly dendritic cells) has made it possible to reliably generate tumor antigen-specific T cells, both in animal models and in humans. These encouraging pre-clinical results have led to a translation of these immunotherapeutic strategies into clinical trials. With numerous trials still underway, their general outcome has so far been disappointing, and the discrepancy between pre-clinical data and clinical response rates is striking. Thus, either the pre-clinical models have not been representative of the human situation or the translation into human clinical trials is still sub-optimal. Here we suggest new avenues of clinical research to further improve cellular cancer immunotherapy.
尽管肿瘤与宿主免疫相互作用的复杂性仍未得到充分理解，但细胞疫苗（尤其是树突状细胞）的使用已使得在动物模型和人类中可靠地产生肿瘤抗原特异性T细胞成为可能。这些令人鼓舞的临床前结果已促使这些免疫治疗策略转化为临床试验。目前仍有众多试验正在进行中，但其总体结果迄今令人失望，临床前数据与临床反应率之间的差异惊人。因此，要么临床前模型不能代表人类情况，要么向人类临床试验的转化仍未达到最佳状态。在此，我们提出临床研究的新途径，以进一步改进细胞癌症免疫疗法。
